Literature DB >> 19162014

Mechanical reperfusion is associated with post-ischemic hemorrhage in rat brain.

Aigang Lu1, Joseph F Clark, Joseph P Broderick, Gail J Pyne-Geithman, Kenneth R Wagner, Pooja Khatri, Thomas Tomsick, Frank R Sharp.   

Abstract

A major complication of recanalization therapy after an acute arterial occlusion in brain is hemorrhagic transformation (HT). Although it is known that prolonged ischemia is important in the development of HT, the role of reperfusion in ischemia-reperfusion induced HT is less well studied. To address the effect of reperfusion on HT, we assessed the incidence and severity of hemorrhage in rats after 5 h of middle cerebral artery occlusion (MCAO) followed by 19-hour reperfusion compared to rats with permanent occlusion (PMCAO) at the same 24-hour time point. The incidence and amount of hemorrhage, neurological function, and mortality rates were measured. MCAO (5 h) with 19-hour reperfusion was associated with a significantly higher incidence of cortical hemorrhage compared to PMCAO (81.8% vs 18.2%, p<0.05). Hemorrhage scores were higher in the 5-hour MCAO/reperfusion group compared to PMCAO rats (17.6+/-11.5 vs 2.4+/-5.3 in cortex, 20.4+/-4.6 vs 9.7+/-4.5 in striatum, p<0.01). Neurological function was worse in the ischemia-reperfusion group compared to PMCAO (p<0.05) and mortality rates were insignificantly higher in the 5-hour MCAO/reperfusion group vs PMCAO group (54.5% vs 18.1%; p<0.08). The results suggest that reperfusion after prolonged ischemia is associated with increased hemorrhagic transformation and neurological deterioration as compared to permanent ischemia. Whether pharmacological treatments prior to reperfusion attenuate post-ischemic HT requires further study.

Entities:  

Mesh:

Year:  2009        PMID: 19162014      PMCID: PMC2659349          DOI: 10.1016/j.expneurol.2008.12.020

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  24 in total

Review 1.  Elements of cerebral microvascular ischaemia.

Authors:  M A Petty; J G Wettstein
Journal:  Brain Res Brain Res Rev       Date:  2001-08

Review 2.  Brain CT scan in acute ischemic stroke: early signs and functional outcome.

Authors:  Nicola Tambasco; Francesco Corea; Roberto Luccioli; Ettore Ciorba; Lucilla Parnetti; Virgilio Gallai
Journal:  Clin Exp Hypertens       Date:  2002 Oct-Nov       Impact factor: 1.749

3.  Quantitative assessment of the normal cerebral microvasculature by endothelial barrier antigen (EBA) immunohistochemistry: application to focal cerebral ischemia.

Authors:  B Lin; M D Ginsberg
Journal:  Brain Res       Date:  2000-05-26       Impact factor: 3.252

4.  Superoxide during reperfusion contributes to caspase-8 expression and apoptosis after transient focal stroke.

Authors:  Y Morita-Fujimura; M Fujimura; T Yoshimoto; P H Chan
Journal:  Stroke       Date:  2001-10       Impact factor: 7.914

5.  The nonpeptide glycoprotein IIb/IIIa platelet receptor antagonist SM-20302 reduces tissue plasminogen activator-induced intracerebral hemorrhage after thromboembolic stroke.

Authors:  Paul A Lapchak; Dalia M Araujo; Donghuan Song; Justin A Zivin
Journal:  Stroke       Date:  2002-01       Impact factor: 7.914

6.  Timing of spontaneous recanalization and risk of hemorrhagic transformation in acute cardioembolic stroke.

Authors:  C A Molina; J Montaner; S Abilleira; B Ibarra; F Romero; J F Arenillas; J Alvarez-Sabín
Journal:  Stroke       Date:  2001-05       Impact factor: 7.914

7.  Hemorrhagic transformation is related to the duration of occlusion and treatment with tissue plasminogen activator in a nonembolic stroke model.

Authors:  Susan C Fagan; Tavarekere N Nagaraja; Joseph D Fenstermacher; Jianqing Zheng; Maribeth Johnson; Robert A Knight
Journal:  Neurol Res       Date:  2003-06       Impact factor: 2.448

8.  Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials.

Authors:  Werner Hacke; Geoffrey Donnan; Cesare Fieschi; Markku Kaste; Rüdiger von Kummer; Joseph P Broderick; Thomas Brott; Michael Frankel; James C Grotta; E Clarke Haley; Thomas Kwiatkowski; Steven R Levine; Chris Lewandowski; Mei Lu; Patrick Lyden; John R Marler; Suresh Patel; Barbara C Tilley; Gregory Albers; Erich Bluhmki; Manfred Wilhelm; Scott Hamilton
Journal:  Lancet       Date:  2004-03-06       Impact factor: 79.321

9.  Reperfusion activates metalloproteinases that contribute to neurovascular injury.

Authors:  Aigang Lu; Joseph F Clark; Joseph P Broderick; Gail J Pyne-Geithman; Kenneth R Wagner; Ruiqiong Ran; Pooja Khatri; Thomas Tomsick; Frank R Sharp
Journal:  Exp Neurol       Date:  2007-12-15       Impact factor: 5.330

10.  Geldanamycin induces heat shock proteins in brain and protects against focal cerebral ischemia.

Authors:  Aigang Lu; Ruiqiong Ran; Sophie Parmentier-Batteur; Alex Nee; Frank R Sharp
Journal:  J Neurochem       Date:  2002-04       Impact factor: 5.372

View more
  17 in total

1.  Intra-arterial iodinated radiographic contrast material injection administration in a rat middle cerebral artery occlusion and reperfusion model: possible effects on intracerebral hemorrhage.

Authors:  Yuko Kurosawa; Aigang Lu; Pooja Khatri; Janice A Carrozzella; Joseph F Clark; Jane Khoury; Thomas A Tomsick
Journal:  Stroke       Date:  2010-04-01       Impact factor: 7.914

Review 2.  Preclinical stroke research--advantages and disadvantages of the most common rodent models of focal ischaemia.

Authors:  I M Macrae
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

3.  Brain distribution and elimination of recombinant human TIMP-1 after cerebral ischemia and reperfusion in rats.

Authors:  Yalian Sa; Jinsong Hao; Divya Samineni; Joseph Clark; Gail Pyne-Geithman; Joseph Broderick; Aigang Lu
Journal:  Neurol Res       Date:  2011-05       Impact factor: 2.448

4.  Peroxynitrite decomposition catalyst prevents matrix metalloproteinase activation and neurovascular injury after prolonged cerebral ischemia in rats.

Authors:  Yalikun Suofu; Joseph Clark; Joseph Broderick; Kenneth R Wagner; Thomas Tomsick; Yalian Sa; Aigang Lu
Journal:  J Neurochem       Date:  2010-10-26       Impact factor: 5.372

Review 5.  Mechanisms in blood-brain barrier opening and metabolism-challenged cerebrovascular ischemia with emphasis on ischemic stroke.

Authors:  Sajad Sarvari; Faezeh Moakedi; Emily Hone; James W Simpkins; Xuefang Ren
Journal:  Metab Brain Dis       Date:  2020-04-15       Impact factor: 3.584

Review 6.  Hemorrhagic transformation after ischemic stroke in animals and humans.

Authors:  Glen C Jickling; DaZhi Liu; Boryana Stamova; Bradley P Ander; Xinhua Zhan; Aigang Lu; Frank R Sharp
Journal:  J Cereb Blood Flow Metab       Date:  2013-11-27       Impact factor: 6.200

7.  Decreased infarct volume and intracranial hemorrhage associated with intra-arterial nonionic iso-osmolar contrast material in an MCA occlusion/reperfusion model.

Authors:  H Morales; A Lu; Y Kurosawa; J F Clark; J Leach; K Weiss; T Tomsick
Journal:  AJNR Am J Neuroradiol       Date:  2014-05-08       Impact factor: 3.825

8.  Outcome Differences between Intra-Arterial Iso- and Low-Osmolality Iodinated Radiographic Contrast Media in the Interventional Management of Stroke III Trial.

Authors:  T A Tomsick; L D Foster; D S Liebeskind; M D Hill; J Carrozella; M Goyal; R von Kummer; A M Demchuk; I Dzialowski; V Puetz; T Jovin; H Morales; Y Y Palesch; J Broderick; P Khatri; S D Yeatts
Journal:  AJNR Am J Neuroradiol       Date:  2015-07-30       Impact factor: 3.825

Review 9.  Recommendations for preclinical research in hemorrhagic transformation.

Authors:  Susan C Fagan; Paul A Lapchak; David S Liebeskind; Tauheed Ishrat; Adviye Ergul
Journal:  Transl Stroke Res       Date:  2013-06       Impact factor: 6.829

10.  Matrix metalloproteinase-2 deletions protect against hemorrhagic transformation after 1 h of cerebral ischemia and 23 h of reperfusion.

Authors:  A Lu; Y Suofu; F Guan; J P Broderick; K R Wagner; J F Clark
Journal:  Neuroscience       Date:  2013-09-12       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.